Literature DB >> 14622242

Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development.

En-Ju D Lin1, Cristina Richichi, Deborah Young, Kristin Baer, Annamaria Vezzani, Matthew J During.   

Abstract

Galanin, a 29- or 30-amino acid neuropeptide, has been implicated in the modulation of seizures. In this study, we constructed a recombinant adeno-associated viral (AAV) vector to constitutively over-express galanin (AAV-GAL). The vector mediated efficient transduction of HEK 293 cells in vitro and robust galanin expression in vivo when injected into the rat dorsal hippocampus. Rats were administered kainic acid intrahippocampally 2.5 months following AAV-GAL or empty vector (AAV-Empty) injection to study the effect of vector-mediated galanin over-expression on seizures. AAV-GAL-injected rats showed a decreased number of seizure episodes and total time spent in seizures compared to AAV-Empty rats, despite similar latencies to development of the first EEG seizure and similar levels of neuronal damage in the CA3 region for both groups. These data show that recombinant AAV mediates strong and stable over-expression of galanin when injected into the rat hippocampus resulting in a significant anticonvulsive effect. The seizure suppression effect of galanin expression in the hippocampus by viral vectors may lead to novel therapeutic strategies for the treatment and management of intractable seizures with focal onset such as temporal lobe epilepsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622242     DOI: 10.1046/j.1460-9568.2003.02926.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  33 in total

Review 1.  Gene therapy for epilepsy.

Authors:  David W McCandless; Jeffrey W McCandless
Journal:  Metab Brain Dis       Date:  2010-09-23       Impact factor: 3.584

Review 2.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

3.  Gene therapy in epilepsy.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

4.  A promising genetic approach for the treatment of epilepsy.

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2004 Jul-Aug       Impact factor: 7.500

Review 5.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

6.  On demand up-regulation of therapeutic genes in the brain: fiction or reality?

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2007 May-Jun       Impact factor: 7.500

7.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

8.  Neurotrophin-3 mRNA a putative target of miR21 following status epilepticus.

Authors:  Rashmi M Risbud; Carolyn Lee; Brenda E Porter
Journal:  Brain Res       Date:  2011-09-24       Impact factor: 3.252

Review 9.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

10.  Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.

Authors:  S Foti; R P Haberman; R J Samulski; T J McCown
Journal:  Gene Ther       Date:  2007-08-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.